MedinCell S.A.
MEDCL.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.23B
Close$
$-26.87
200.2% downside
Current Fair Value
200.2% downsideOvervalued by 200.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.23 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.87 |
| Beta | 0.97 |
| Outstanding Shares | 35,904,000 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -31.93 |
|---|---|
| PEG | -10.9 |
| Price to Sales | 26.82 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
December 8, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$17.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About MedinCell S.A.
150 employees
CEO: Christophe Douat MedinCell S.A. is a pharmaceutical company dedicated to creating a diverse array of medical treatments. At the heart of its innovation is the BEPO platform, a unique technology designed for long-acting injectable drugs. This system utili...